PILOT STUDY--HERPES SIMPLEX VIRUS FOR GENE THERAPY FOR LESCH-NYHAN SYNDROME

试点研究——单纯疱疹病毒用于 LESCH-NYHAN 综合征的基因治疗

基本信息

  • 批准号:
    2374251
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

Many genetic diseases affect the nervous system. The long term goal of this grant proposal is to develop avirulent herpes simplex virus type 1 (HSV-1) strains as gene therapy vectors for nervous system disorders. There are two characteristics of HSV-1 infections that will be exploited to achieve this goal: HSV-1 establishes life-long latent infections in neurons, and during latent infection only a single viral promoter is active. This promoter directs the synthesis of the HSV-1 latency associated transcripts (LATs), which are expressed for the lifetime of the latently infected individual. To demonstrate the feasibility of HSV-1- mediated gene therapy, a cDNA for the human hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene will be placed under the control of the HSV-1 LAT gene promoter. A complete deficiency of HPRT causes Lesch- Nyhan syndrome, a severe and untreatable neurological disease. Since individuals with very low HPRT levels are spared from neurological dysfunction, even partial replacement of HPRT in the nervous system may be therapeutic. HPRT-negative transgenic mice are available as an animal model of Lesch-Nyhan syndrome to assess the effectiveness of gene transfer techniques. There are several avirulent HSV-1 strains available, both replication competent and incompetent. These viruses do not produce any disease in mice, even when inoculated intracerebrally (k.c.). To develop HSV-1 for gene delivery to the nervous system, we will i) study several avirulent HSV-1 strains for spread through the nervous system, cytopathology, viral RNA and protein expression during acute infection, and the type, number and distribution of LAT expressing cells during latency, ii)determine the polyA+/regulatory sequence requirements for high levels of HSV-1 latency promoter directed cDNA expression in the most promising avirulent strains(s), and iii) investigate the tissue distribution of human HPRT mRNA and proteins in normal mice and in HPRT- negative transgenic mice infected with the HSV-1/HPRT recombinants.
许多遗传性疾病影响神经系统。的长期目标

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

其他文献

2022 Academy Member Benefits Update
  • DOI:
    10.1016/j.jand.2023.02.007
  • 发表时间:
    2023-04-01
  • 期刊:
  • 影响因子:
  • 作者:
  • 通讯作者:
Toward Social Hospital -snapshot of medical information technologies
走向社会医院——医疗信息技术快照
  • DOI:
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    0
  • 作者:
    鈴木 真生; ;若尾 あすか;松村 耕平;野間 春生;Tomohiro Kuroda
  • 通讯作者:
    Tomohiro Kuroda
Structure and Magnetic Property of Spinel Ferrite Nanosheets Synthesized by Hydrothermal Method
水热法合成尖晶石铁氧体纳米片的结构与磁性能
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yuki Kamei ; Yuki Makinose ; Ken-ichi Katsumata ; ; NOBUHIRO MATSUSHITA
  • 通讯作者:
    NOBUHIRO MATSUSHITA
健康維持のための行動変容を働きかけるソーシャルシステムの開発
开发鼓励行为改变以保持健康的社会系统
  • DOI:
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    0
  • 作者:
    鈴木 真生; ;若尾 あすか;松村 耕平;野間 春生
  • 通讯作者:
    野間 春生
微細加工による医療・創薬のためのバイオデバイス開発
通过微加工开发用于医疗和药物发现的生物设备
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yuki Kamei ; Yuki Makinose ; Ken-ichi Katsumata ; ; NOBUHIRO MATSUSHITA;H. Ago;一木隆範
  • 通讯作者:
    一木隆範

的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString(' ', 18)}}的其他基金

Preclinical Services for Antibacterial Resistance Biopharmaceutical Product Development
抗菌药物耐药性生物制药产品开发的临床前服务
  • 批准号:
    10934774
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Preclinical Services for Biopharmaceutical Product Development
生物制药产品开发的临床前服务
  • 批准号:
    10934767
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
AWARD PINMED SBIR TOPIC #114 PHASE I
PINMED SBIR 主题奖
  • 批准号:
    10974171
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Pharmacology Consulting Services in relation to Pharmaceutical Development with Pain expertise. 09/12/2023 - 09/11/2024
与具有疼痛专业知识的药物开发相关的药理学咨询服务。
  • 批准号:
    10949065
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
FRAMINGHAM HEART STUDY - TASK AREA C - GENETIC RESULTS REPORTING
弗雷明汉心脏研究 - 任务领域 C - 基因结果报告
  • 批准号:
    10974185
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
FRAMINGHAM HEART STUDY - YEAR 5 EXAM
弗雷明汉心脏研究 - 五年级考试
  • 批准号:
    10953248
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Virtual Kick off Meeting with NCI for MAS Analysis Pool
与 NCI 举行 MAS 分析池虚拟启动会议
  • 批准号:
    10974493
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - UNIVERSITY OF MINNESOTA FIELD CENTER.
年轻人冠状动脉风险发展 (CARDIA) 研究 - 明尼苏达大学实地中心。
  • 批准号:
    10901060
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - COORDINATING CENTER (CC)
年轻人冠状动脉风险发展 (CARDIA) 研究 - 协调中心 (CC)
  • 批准号:
    10901063
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of Therapeutics for DENGUE VIRUS
登革热病毒治疗方法的开发
  • 批准号:
    10938081
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Gene expression profiling of skin ulcers for short-acting in vivo gene therapy
皮肤溃疡的基因表达谱用于短效体内基因治疗
  • 批准号:
    23K19673
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Advancing the UCOE-based gene expression platform fo r improved bioma nufacturing and gene therapy applications.
推进基于 UCOE 的基因表达平台,以改善生物制造和基因治疗应用。
  • 批准号:
    1668272
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
    Studentship
Advancing the UCOE-based gene expression platform for improved biomanufacturing and gene therapy applications
推进基于 UCOE 的基因表达平台,以改进生物制造和基因治疗应用
  • 批准号:
    BB/M016390/1
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
    Training Grant
The Establishment of Gene Therapy with and Gene Expression Regulation of Adenoviral Vector Serotype 35
35型腺病毒载体基因治疗的建立及基因表达调控
  • 批准号:
    21592242
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of Renin-angiotensin axis on its gene expression and anti-sense gene therapy in patients with neuropathic pain
肾素-血管紧张素轴对其基因表达的影响及神经病理性疼痛患者的反义基因治疗
  • 批准号:
    14571429
  • 财政年份:
    2002
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Modeling gene therapy of Hemophilia A via liver directed gene expression
通过肝脏定向基因表达模拟 A 型血友病的基因治疗
  • 批准号:
    6664067
  • 财政年份:
    2002
  • 资助金额:
    --
  • 项目类别:
Gene expression in myocarditis and dilated cardiomyopathy and basic study of gene therapy by plasmid
心肌炎和扩张型心肌病基因表达及质粒基因治疗基础研究
  • 批准号:
    14570645
  • 财政年份:
    2002
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Modeling gene therapy of Hemophilia A via liver directed gene expression
通过肝脏定向基因表达模拟 A 型血友病基因治疗
  • 批准号:
    6501562
  • 财政年份:
    2001
  • 资助金额:
    --
  • 项目类别:
Development of stable and regulated gene expression system for gene therapy
开发用于基因治疗的稳定且受调控的基因表达系统
  • 批准号:
    12672145
  • 财政年份:
    2000
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Modeling gene therapy of Hemophilia A via liver directed gene expression
通过肝脏定向基因表达模拟 A 型血友病基因治疗
  • 批准号:
    6365585
  • 财政年份:
    2000
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了